These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35852914)

  • 21. Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn's Disease Patients.
    Repnik K; Koder S; Skok P; Ferkolj I; Potočnik U
    Biochem Genet; 2016 Aug; 54(4):476-486. PubMed ID: 27115882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation Between Ultrasonographic Response and Anti-Tumor Necrosis Factor Drug Levels in Crohn's disease.
    Han ZM; Elodie WH; Yan LH; Xu PC; Zhao XM; Zhi FC
    Ther Drug Monit; 2022 Oct; 44(5):659-664. PubMed ID: 35427284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of linkage between lymphotoxin alpha haplotype and polymorphisms in 5'-flanking region of tumor necrosis factor alpha gene associated with efficacy of infliximab for Crohn's disease patients.
    Ozeki T; Furuya Y; Nagano C; Matsui C; Takayanagi R; Yokoyama H; Yamada Y
    Mutat Res; 2006 Dec; 602(1-2):170-4. PubMed ID: 17049565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas.
    De Gregorio M; Lee T; Krishnaprasad K; Amos G; An YK; Bastian-Jordan M; Begun J; Borok N; Brown DJM; Cheung W; Connor SJ; Gerstenmaier J; Gilbert LE; Gilmore R; Gu B; Kutaiba N; Lee A; Mahy G; Srinivasan A; Thin L; Thompson AJ; Welman CJ; Yong EXZ; De Cruz P; van Langenberg D; Sparrow MP; Ding NS
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1306-1314. PubMed ID: 34389484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease.
    Alfaro I; Masamunt MC; Planell N; López-García A; Castro J; Gallego M; Barastegui R; Giner A; Vara A; Salas A; Ricart E; Panés J; Ordás I
    World J Gastroenterol; 2019 Apr; 25(14):1764-1774. PubMed ID: 31011260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn's disease.
    Yamamoto K; Chiba T; Matsumoto T
    World J Gastroenterol; 2015 Sep; 21(35):10208-14. PubMed ID: 26401086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.
    Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R
    J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
    Clark-Snustad KD; Singla A; Lee SD
    Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease.
    Matsukura H; Ikeda S; Yoshimura N; Takazoe M; Muramatsu M
    Aliment Pharmacol Ther; 2008 May; 27(9):765-70. PubMed ID: 18248655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn's Disease.
    Urabe S; Isomoto H; Ishida T; Maeda K; Inamine T; Kondo S; Higuchi N; Sato K; Uehara R; Yajima H; Machida H; Chen CC; Fukuda Y; Takeshima F; Nakao K; Tsukamoto K
    Biomed Res Int; 2015; 2015():416838. PubMed ID: 26558270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
    Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M
    PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.
    Barber GE; Yajnik V; Khalili H; Giallourakis C; Garber J; Xavier R; Ananthakrishnan AN
    Am J Gastroenterol; 2016 Dec; 111(12):1816-1822. PubMed ID: 27596696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment.
    Andreou NP; Legaki E; Dovrolis N; Boyanov N; Georgiou K; Gkouskou K; Gazouli M
    Dig Liver Dis; 2021 May; 53(5):574-580. PubMed ID: 33339749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
    BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study.
    van Haaften WT; Mortensen JH; Dige AK; Grønbæk H; Hvas CL; Bay-Jensen AC; Karsdal MA; Olinga P; Manon-Jensen T; Dijkstra G
    Clin Transl Gastroenterol; 2020 Sep; 11(9):e00217. PubMed ID: 33094957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Prospective Pharmacogenomic Study of Crohn's Disease Patients during Routine Therapy with Anti-TNF-α Drug Adalimumab: Contribution of ATG5, NFKB1, and CRP Genes to Pharmacodynamic Variability.
    Deželak M; Repnik K; Koder S; Ferkolj I; Potočnik U
    OMICS; 2016 May; 20(5):296-309. PubMed ID: 27096233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
    Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
    J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence.
    Collins M; Sarter H; Gower-Rousseau C; Koriche D; Libier L; Nachury M; Cortot A; Zerbib P; Blanc P; Desreumaux P; Colombel JF; Peyrin-Biroulet L; Pineton de Chambrun G
    J Crohns Colitis; 2017 Mar; 11(3):281-288. PubMed ID: 27578800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.